# Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia

> **NCT03118128** · NA · COMPLETED · sponsor: **Hospital General de Mexico** · enrollment: 102 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03118128
- **Lead sponsor:** Hospital General de Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2016-12-01
- **Final completion:** 2017-04-30
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118128, "Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03118128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*